Corticosteroids are extensively used in medicine for their powerful anti-inflammatory and immunosuppressive effects. However, their psychiatric side effects—such as mood disturbances, anxiety, and psychosis—are significant yet often underappreciated. This review provides a comprehensive exploration of corticosteroid-induced psychiatric disorders, with a focus on their underlying mechanisms and clinical implications. We examine how corticosteroids influence the hypothalamic–pituitary–adrenal (HPA) axis, leading to the dysregulation of stress responses and alterations in neurotransmitter levels, particularly dopamine, serotonin, and glutamate. These changes are linked to structural abnormalities in key brain areas such as the hippocampus and amygdala, which are implicated in mood and anxiety disorders, psychosis, and conditions like post-traumatic stress disorder (PTSD) and eating disorders. This review highlights the need for healthcare providers to be vigilant in recognizing and managing corticosteroid-induced psychiatric symptoms, especially in vulnerable populations with pre-existing mental health conditions. The complex relationship between corticosteroid type, dose, duration, and mental health outcomes is explored, emphasizing the importance of personalized treatment approaches to mitigate psychiatric risks. Given the widespread use of corticosteroids, there is an urgent need for more focused research on their psychiatric side effects. This review underscores the importance of patient education and careful monitoring to ensure optimal therapeutic outcomes while minimizing mental health risks associated with corticosteroid therapy.

Caffeine and chlorogenic acid are among the most extensively investigated bioactive compounds in coffee, tea, and other plant-derived products due to their noteworthy physical, nutritional, and industrial relevance. Caffeine is primarily acknowledged for its central nervous system stimulant activity, whereas chlorogenic acid, a phenolic ester, contributes antioxidant, anti-inflammatory, and metabolic health benefits. This review was conducted according to the PRISMA guidelines in order to systematically compile and summarize the extraction and analytical conditions reported for caffeine and CGAs in different matrices and to provide a structured comparison among the reported studies. All studies focusing on the extraction and/or quantification of caffeine and chlorogenic acids in several matrices were considered eligible. Three independent electronic searches were performed using PubMed, Science.gov, and BASE to identify relevant articles. Extraction of data was conducted independently by four authors based on consistent selection and extraction criteria. One hundred and twenty-five studies were identified. The results were summarized in tables including several parameters. Conventional extraction techniques, including aqueous and organic solvent-based methods, have formed the foundation for separating caffeine and chlorogenic acids. However, rising interest in green and sustainable technologies has shifted attention towards advanced approaches such as ultrasound-assisted extraction and microwave-assisted extraction. These methods not only enhance extraction yields and reduce processing times but also align with environmental and safety concerns in the modern food and pharmaceutical industries. For quantification, high-performance liquid chromatography equipped with ultraviolet or mass spectrometric detection remains the benchmark, offering precision and reproducibility in different matrices. This review sheds light on recent advances and ongoing research in the extraction and quantification of caffeine and chlorogenic acid in different types of matrices. Continued innovation in green extraction technologies and robust quantification methods is essential for supporting scientific research applications.

Corticosteroids are extensively used in medicine for their powerful anti-inflammatory and immunosuppressive effects. However, their psychiatric side effects—such as mood disturbances, anxiety, and psychosis—are significant yet often underappreciated. This review provides a comprehensive exploration of corticosteroid-induced psychiatric disorders, with a focus on their underlying mechanisms and clinical implications. We examine how corticosteroids influence the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to dysregulation of stress responses and alterations in neurotransmitter levels, particularly dopamine, serotonin, and glutamate. These changes are linked to structural abnormalities in key brain areas such as the hippocampus and amygdala, which are implicated in mood and anxiety disorders, psychosis, and conditions like post-traumatic stress disorder (PTSD) and eating disorders. This review highlights the need for healthcare providers to be vigilant in recognizing and managing corticosteroid-induced psychiatric symptoms, especially in vulnerable populations with pre-existing mental health conditions. The complex relationship between corticosteroid type, dose, duration, and mental health outcomes is explored, emphasizing the importance of personalized treatment approaches to mitigate psychiatric risks. Given the widespread use of corticosteroids, there is an urgent need for more focused research on their psychiatric side effects. This review underscores the importance of patient education and careful monitoring to ensure optimal therapeutic outcomes while minimizing mental health risks associated with corticosteroid therapy.